Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

OBJECTIVE: This study aims to systematically validate the performance of surrogate endpoints in phase II and III clinical trials for NSCLC patients under various trial settings. METHODS: A literature search retrieved all registered phase II and III trials of NSCLC patients in which OS, with at least...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Tiantian, Gao, Yuan, Zhang, Ruyang, Wei, Yongyue, Chen, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520950/
https://www.ncbi.nlm.nih.gov/pubmed/36171546
http://dx.doi.org/10.1186/s12885-022-10046-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520950/
https://www.ncbi.nlm.nih.gov/pubmed/36171546
http://dx.doi.org/10.1186/s12885-022-10046-z

Ejemplares similares